WASHINGTON, May 22, 2018 /PRNewswire-USNewswire/ -- Wounded Warrior Project® (WWP) is pleased and supportive of the president's nomination of Robert Wilkie to become the next Secretary of Veterans Affairs (VA). In his tenure as Acting Secretary, Wilkie has demonstrated tremendous ability to lead and focus on the issues of highest concern in the veteran community.
"Before the Senate even begins his confirmation process, Mr. Wilkie will have already placed VA on a path to modernizing its health records and helped bring Congress to the precipice of passing groundbreaking expansions to community care and caregiver assistance programs," said René Bardorf, WWP senior vice president of government and community relations. "We look forward to continuing to work alongside VA leadership to help deliver on our mission to honor and empower Wounded Warriors, and we are confident Mr. Wilkie will continue to demonstrate the experience, skills, and passion to become the transformative leader our veterans deserve."
About Wounded Warrior Project Since 2003, Wounded Warrior Project® (WWP) has been meeting the growing needs of warriors, their families, and caregivers ? helping them achieve their highest ambition. Learn more: http://newsroom.woundedwarriorproject.org/about-us.
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument?
?QOL-B...
Jarrard Inc., a leading national healthcare strategic communications consultancy, has expanded by 10 percent, adding seven new professionals to address the increasing demand for its healthcare advisory services. The team now includes 81 full-time...
Pulse Biosciences, Inc. ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that the Company's Board of Directors has determined a new record...
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of...
Illumina, Inc. announced today that Anna Richo has joined the company's Board of Directors following shareholder approval of the director slate at the company's May 16, 2024, annual meeting. Ms. Richo currently serves as Corporate Senior Vice...
